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Abstract
The HIV-associated tuberculosis (TB) epidemic remains a huge challenge to public health in resource-limited
settings. Reducing the nearly 0.5 million deaths that result each year has been identified as a key priority. Major
progress has been made over the past 10 years in defining appropriate strategies and policy guidelines for early
diagnosis and effective case management. Ascertainment of cases has been improved through a twofold strategy
of provider-initiated HIV testing and counseling in TB patients and intensified TB case finding among those living
with HIV. Outcomes of rifampicin-based TB treatment are greatly enhanced by concurrent co-trimoxazole prophylaxis
and antiretroviral therapy (ART). ART reduces mortality across a spectrum of CD4 counts and randomized controlled
trials have defined the optimum time to start ART. Good outcomes can be achieved when combining TB treatment
with first-line ART, but use with second-line ART remains challenging due to pharmacokinetic drug interactions
and cotoxicity. We review the frequency and spectrum of adverse drug reactions and immune reconstitution
inflammatory syndrome (IRIS) resulting from combined treatment, and highlight the challenges of managing
HIV-associated drug-resistant TB.
Introduction
The global epidemics of HIV/AIDS and tuberculosis (TB)
both remain huge challenges to international public health,
causing illness and death in millions of people worldwide
each year (Table 1) [1]. TB is the most important AIDS-
related opportunistic disease globally and is the leading
cause of HIV/AIDS-related mortality, accounting for an
estimated 25% of such deaths [2,3]. Sub-Saharan Africa
suffers disproportionately, with 79% of global cases of HIV-
associated TB [1]. In the countries of southern and eastern
Africa where HIV prevalence is highest, the impact of HIV
has severely undermined TB control over the past 20 years
[4]. The global co-epidemic has been further compounded
in recent years by the emergence of the growing challenge
of multi-drug resistant TB (MDR-TB) [5,6].
The World Health Organization (WHO) DOTS (dir-
ectly observed treatment, short-course) TB control strat-
egy used in isolation provides far from optimum case
management for individual patients with HIV-associated
TB and it has failed to control TB at a population level in
settings with high HIV prevalence [2,7]. Comprehensive
packages of additional interventions are needed to address
the consequences of HIV in TB patients and to reduce the
burden of TB in those living with HIV infection [8]. An in-
terim policy on collaborative TB/HIV activities was first
published by WHO in 2004 [9] and approximately 1.3 mil-
lion lives are estimated to have been saved by these inter-
ventions by 2011 [1]. An updated policy (Table 2) [10]
published in 2012 provides the overall policy framework
for addressing HIV-associated TB and specific recommen-
dations on management of HIV, TB and multidrug-
resistant (MDR)-TB are provided by individual guideline
documents [11-13] (Table 3).
This article provides an up-to-date review of the current
medical management of adult patients with HIV-associated
TB. We review case ascertainment as the critical first
step and then how clinical outcomes can be optimized
by provision of effective TB treatment, use of concur-
rent ART, prevention of HIV-related comorbidities and
management of drug cotoxicity and immune reconsti-
tution inflammatory syndrome (IRIS). We also describe
the management of HIV-associated MDR-TB. However,
the management of children, models of integrated TB and
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HIV care delivery and prevention of TB in people living
with HIV using ART and isoniazid preventive therapy lie
outside the scope of this review.
Diagnosis of HIV-associated TB
The prerequisite for optimum management of HIV-
associated TB is early and accurate diagnosis and, for
many years, this has been a key obstacle. Case ascertain-
ment can be greatly improved by high rates of quality-
assured HIV testing among those being investigated for
TB as well as high rates of screening for TB in those liv-
ing with HIV.
Screening for TB in those living with HIV infection
In high burden settings, much prevalent TB disease re-
mains ‘below the radar’ in those living with HIV. Postmor-
tem studies conducted in hospitals across sub-Saharan
Africa over the past 20 years have repeatedly shown that
between 30% and 50% of HIV-infected adult inpatients
who die have postmortem evidence of TB, much of which
was neither clinically suspected nor diagnosed before
death [14-17]. These studies have highlighted the abject
failure of the diagnostic process and the low sensitivity of
diagnostic tools available [18]. In the absence of more sen-
sitive means of diagnosis, management algorithms for sus-
pected sputum smear-negative disease were developed
[19-21] and studies of empirical TB treatment for certain
high risk patient groups with advanced immunodeficiency
are being conducted [22].
However, in recent years there have been significant
advances in screening and diagnosis. Traditional symptom
screening for pulmonary TB based on chronic cough
has low sensitivity for HIV-associated TB [23,24]. A new
WHO symptom screening tool for HIV-associated TB
Table 1 Burden of HIV infection, tuberculosis (TB) and HIV-associated TB globally and in sub-Saharan Africa
Disease Global burden Burden in sub-Saharan Africa: (% of global burden)
HIV/AIDS:
No. of people living with HIV infection 34,200,000 23,500,000 (69%)
HIV/AIDS-related deaths 1,700,000 1,200,000 (71%)
Tuberculosis:
No. of incident cases of TB 8,700,000 2,300,000 (26%)
TB deaths (excluding HIV) 990,000 220,000 (22%)
Incident cases of multidrug-resistant TB 310,000 45,000 (15%)
HIV-associated tuberculosis:
No. of incident cases 1,100,000 870,000 (79%)
No. of HIV-associated TB deaths 430,000 300,000 (70%)
Data from [1,3]. Incident disease and deaths represent annual disease burden.
Table 2 World Health Organization (WHO)-recommended collaborative tuberculosis (TB)/HIV activities (adapted from [10])
Key area Points of action
Establish and strengthen the mechanisms for
delivering integrated TB and HIV services
Set up and strengthen a coordinating body for collaborative TB/HIV activities
Determine the HIV prevalence among TB patients and the TB prevalence among
HIV patients
Carry out joint TB/HIV planning to integrate the delivery of TB and HIV services
Monitor and evaluate collaborative TB/HIV activities
Reduce the burden of TB in people living with
HIV (early ART plus the three Is)
Intensify TB case finding and ensure high quality TB treatment
Initiate TB prevention using isoniazid preventive therapy and early antiretroviral
therapy (ART)
Ensure control of TB infection in healthcare facilities and congregate settings
Reduce the burden of HIV in patients with diagnosed
TB and those under investigation for TB
Provide HIV testing and counseling to both groups of patients
Provide HIV preventive interventions to both groups of patients
Provide co-trimoxazole preventive therapy for TB patients living with HIV
Provide HIV prevention interventions, treatment and care for TB patients living
with HIV
Provide antiretroviral therapy for TB patients living with HIV
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(one or more of the following symptoms: cough, fever,
weight loss or night sweats, each of any magnitude or dur-
ation) has much higher sensitivity and is recommended
for routine screening of those in HIV care at each visit
[25]. However, in view of its low specificity, further re-
search is needed to define which of the large number of
patients with a positive screen should be prioritized for
subsequent microbiological testing of clinical samples.
New diagnostic tools have also increased our capacity
for microbiological diagnosis. This includes the Xpert
MTB/RIF assay, which was endorsed by WHO in 2010. A
single test is able to detect all sputum smear-positive dis-
ease, approximately 70% of smear-negative pulmonary dis-
ease and provides rapid simultaneous screening for RIF
resistance [26]. In addition, this assay can be used to test a
wide range of extrapulmonary sample types [26,27]. The
Xpert MTB/RIF assay has been incorporated into the na-
tional guidelines of many high burden countries. In South
Africa, which alone accounts for approximately 30% of the
global burden of HIV-associated TB, sputum smear mi-
croscopy has now been replaced by Xpert MTB/RIF as the
initial diagnostic test for TB [26].
Determine TB-LAM is a low-cost, point-of-care lateral-
flow (‘strip test’) assay that diagnoses TB through detection
in urine of lipoarabinomannan (LAM): a lipopolysaccharide
component of the M. tuberculosis cell wall [28]. It has
high specificity whereas sensitivity is very strongly CD4
count dependent, at best detecting approximately two-
thirds of cases in those with CD4 counts <50 cells/μl
[28-31]. This assay therefore allows rapid (<30 minutes)
bedside diagnosis among those who have the highest
mortality risk [32]. The growing evidence base on this
assay will be reviewed by WHO in 2014. Its role is likely
to be as an add-on test within the diagnostic algorithm to
permit point-of-care diagnosis and immediate TB treat-
ment among patients with advanced immunodeficiency
(CD4 counts <200 cells/μl) following admission to hospital
or enrolling in ARTclinics [28,31].
Screening for HIV in those with TB or possible TB
A major step forward in improving HIV testing rates in
patients with TB was the switch from voluntary counseling
and testing (VCT) to provider-initiated testing and coun-
seling (PITC) in 2007 [33]. With PITC, all patients
undergo routine testing unless they specifically opt out.
Testing has increased globally from 3.1% in 2004 to 40%
of notified TB cases in 2011, but falls well short of the goal
of universal testing [1]. Testing rates have reached 69% in
Africa, >50% in the Americas and 32% in South-East Asia.
In African countries, the proportion of TB patients testing
positive is 46% overall (range, 8% to 77%) and exceeds
50% in ten counties in the south and east of the continent
[1]. A further significant policy change has been to expand
PITC to include all patients being investigated for TB re-
gardless of whether or not TB is diagnosed [10,12]. This
change resulted from the observed high HIV prevalence
and mortality among those presenting for investigation of
possible TB even when this diagnosis was subsequently ex-
cluded [34]. It is critical, however, that improved testing
rates are accompanied by improvement in the delivery of
appropriate management.
Optimized TB treatment
The first priority for patients with HIV-associated TB is to
immediately start effective TB treatment using a regimen
containing RIF throughout [12,35]. A systematic review
found that the incidence of relapse and/or failure among
patients treated with intermittent (thrice weekly) TB ther-
apy throughout was two to three times higher than that in
patients who received a daily intensive phase [36]. Thus,
the recommended optimum standard regimen is 2 months
of rifampicin, isoniazid, pyrazinamide and ethambutol
Table 3 World Health Organization (WHO) policy guidelines on collaborative tuberculosis (TB)/HIV activities and the
management of HIV infection, TB and multidrug-resistant TB (MDR-TB)
Guidelines/year Details Reference
Guidelines for collaborative TB/HIV activities (2012) World Health Organization. WHO policy on collaborative TB/HIV activities.
Guidelines for national programmes and stakeholders. 2012. World Health
Organization, Geneva. WHO/HTM/TB/2012.1. http://whqlibdoc.who.int/
publications/2012/9789241503006_eng.pdf
[10]
Antiretroviral treatment guidelines (2013) World Health Organization. Consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection. Recommendations for a public
health approach, June 2013. WHO, Geneva. Accessible at: http://apps.who.
int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
[11]
Tuberculosis treatment guidelines (2010) World Health Organization. Treatment of tuberculosis: guidelines - fourth edition.
World Health Organization, Geneva, 2010. WHO/HTM/TB/2009.420 Accessible
at: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf
[12]
Drug-resistant TB treatment guidelines (2011) World Health Organization. Guidelines for the management of drug-resistant
tuberculosis: 2011 update. WHO, Geneva. WHO/HTM/TB/2011.6. Accessible at:
http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.
[13]
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followed by 4 months of rifampicin and isoniazid (2HRZE/
4HR), with therapy administered daily throughout [12].
Where this is not possible, an acceptable alternative is to
use a thrice-weekly continuation phase. Treatment out-
comes are worse for those with isoniazid monoresistance
[36,37] and, thus, in settings with high prevalence of iso-
niazid monoresistance, 2HRZE/4HRE is the recommended
first-line regimen [12]. Drug susceptibility testing is rec-
ommended to guide treatment in patients who have previ-
ously been treated for TB, although ideally all patients
with TB should have drug susceptibility testing. Where the
Xpert MTB/RIF assay is being rolled out as the primary
TB diagnostic test, RIF resistance screening is now integral
to the initial diagnostic process [26].
After several decades with no new advances in TB treat-
ment, there are now some promising developments. For
example, several large-scale phase III randomized con-
trolled trials (including the ReMOX, Oflotub and RIFA-
QUIN studies) are evaluating whether incorporation of a
newer fluoroquinolone into treatment regimens can be
used to shorten treatment for drug susceptible TB [38].
The first of these to report, the RIFAQUIN study, found
treatment shortening was associated with a higher rate of
adverse outcomes including failure, relapse and death [39].
However, none of these studies have been designed to spe-
cifically address this question in HIV-infected clinical pop-
ulations. There is also a growing developmental pipeline
of new TB drugs, although these are most likely to be used
in the treatment of MDR-TB, at least initially [38].
Co-trimoxazole preventive therapy
Co-trimoxazole (trimethoprim sulfamethoxazole) is a low-
cost, widely available and relatively safe antibiotic that re-
duces morbidity and mortality in people living with HIV
due to prophylactic activity against a range of pathogens,
including those causing bacterial sepsis, pneumocystis
pneumonia, cerebral toxoplasmosis and malaria. Both ob-
servational and randomized controlled trials conducted in
sub-Saharan Africa have shown that this simple interven-
tion is associated with a substantial reduction in mortality
among patients with HIV-associated TB (range, 19% to
46%) [40-44] (Table 4). This beneficial effect was observed
in a range of settings with high or low rates of bacterial re-
sistance to the drug and is additive in reducing early mor-
tality when combined with ART [45].
Routine administration of co-trimoxazole to patients
with HIV-associated TB is recommended (480 mg
twice per day or 960 mg once per day) [10-12]. Imple-
mentation of this simple, life-saving intervention has
steadily increased from a negligible proportion in 2004
to 79% of all notified TB cases with a positive HIV test
in 2011 (79% of those in the African region and 89% of
those in the South-East Asian region) [1]. Coverage
needs to increase to the 100% target set in the Global
Plan to Stop TB, 2011-2015 [46]. Evidence is unclear as
to whether co-trimoxazole should be continued indefin-
itely or might be discontinued once the CD4 cell count
has reached a threshold of either 200 or 350 cells/μl [11].
The potential benefits of ongoing therapy may vary ac-
cording to local factors such as the safety of the water
supply, the presence of malaria and the local spectrum of
opportunistic pathogens.
Antiretroviral treatment
In observational cohort studies, concurrent ART reduces
mortality risk by 64% to 95% in patients receiving treat-
ment for HIV-associated TB [47]. In the South African
Starting Antiretroviral Therapy at Three Points in Tu-
berculosis Therapy (SAPIT) randomized trial, receipt of
concurrent ART was associated with survival benefit
among those with CD4 cell counts of <200 cells/μl and
200 to 500 cells/μl [48]. Recommended first-line ART
regimens for use with TB treatment are based on non-
nucleoside reverse transcriptase inhibitors (NNRTI),
with efavirenz (EFV) as the preferred choice and nevira-
pine (NVP) as an alternative. While first-line regimen
choices are well established, second-line ART remains
problematic. The recommended regimens and their
pharmacokinetic interactions with TB treatment are
shown in Table 5 and the hiv-druginteractions.org web-
site provides a useful up-to-date source of information
on interactions (see [49]). Combining the multidrug reg-
imens used to treat TB and HIV is complicated not only
by high pill burden and increased risks of drug-drug in-
teractions, but also by cotoxicity and immune reconsti-
tution inflammatory syndrome (IRIS).
Pharmacokinetic interactions with first-line ART
Although RIF induces the expression of cytochrome
P450 2B6 (CYP2B6), which comprises the main meta-
bolic pathway for EFV, studies have failed to demon-
strate significantly reduced concentrations of EFV with
concomitant RIF-based TB treatment [50-53]. This is
consistent with the observed virological responses which
are excellent in patients receiving RIF-based TB treat-
ment treated with standard 600 mg daily doses of EFV
[54-57] and were better than those in TB patients ran-
domized to NVP-based ART in the recent CARINEMO
trial [56]. Similarly, lowering the dose of EFV to 400 mg
daily in the ENCORE1 trial did not compromise out-
comes in non-TB patients [58]. Thus, although the US
Federal Drug Administration (FDA) [59] recommends
that the dose of EFV during RIF treatment is increased
in adults weighing more than 50 kg, this is not sup-
ported by studies in TB patients [53] and is not recom-
mended by the WHO for resource-limited settings.
Conversely, however, among patients with a slow
CYP2B6 metabolizer genotype, EFV concentrations are
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increased during TB treatment, possibly due to inhib-
ition by INH of accessory pathways metabolizing EFV
[60,61]. This genotype is relatively common in Africa,
South-East Asia, and the Caribbean [50-52,62,63]. Whether
EFV-induced central nervous system (CNS) adverse ef-
fects are more frequent during TB treatment or isoniazid
preventive therapy in patients with this genotype needs to
be evaluated.
NVP is a reasonably safe, acceptable alternative for TB
patients unable to tolerate EFV. Through induction of
the expression of CYP2B6, RIF treatment reduces NVP
concentrations by an average of approximately 40% and
NVP-based ART remains inferior to EFV-based regi-
mens in TB patients [56]. During the 14-day lead-in
phase of NVP dosing, plasma drug concentrations are
very low in patients receiving RIF, potentially predispos-
ing to the development of viral resistance mutations and
contributing to an increased risk of virological failure
[54]. The CARENIMO trial recently found that NVP
was well tolerated when introduced at full doses (200
mg twice a day) in patients with CD4 cell counts <250
cells/mm3 receiving RIF [56]. The use of a dose escal-
ation lead-in phase to avoid toxicity in patients receiving
RIF is therefore not recommended.
Table 5 Approaches to cotreatment for HIV-infected patients with rifampicin-susceptible tuberculosis
Combined regimens Treatment recommendations Drug-drug interactions
Efavirenz + rifampicin-based
TB treatment
No dose adjustments TDF + 3TC/FTC + EFV
(WHO-recommended optimum regimen)
AZT + 3TC + EFV (alternative WHO regimen)
Rifampicin induces CYP2B6 but inhibition of CYP2A6 by
isoniazid might account for increased efavirenz
concentrations during TB treatment in those patients with
slow CYP2B6 metabolizer genotype
Nevirapine + rifampicin-based
TB treatment
Omit 14 day lead-in phase of once daily dose of
NVP TDF + 3TC/FTC + NVP (alternative WHO regimen)
AZT + 3TC + NVP (alternative WHO regimen)
Rifampicin induces CYP2B6 and CYP3A4. Although TB
treatment reduces nevirapine concentrations, toxicity
concerns curtail increasing the dose and outcomes are
acceptable (but inferior to EFV) on standard doses.
Lopinavir/ritonavir + rifampicin-
based TB treatment
Double dose lopinavir/ritonavir (800/200 mg
12 hourly) Or superboost lopinavir (lopinavir/
ritonavir 400/400 mg 12 hourly) Monitor alanine
transaminase (ALT) closely.
Rifampicin induces CYP3A4, p-glycoprotein and OATP1B1.
Ritonavir counteracts this effect and adjusted doses of
ritonavir or lopinavir/ritonavir are used to compensate, but
lopinavir concentrations may be more variable. Increased
risk of hepatotoxicity, and gastrointestinal side effects.
PI/ritonavir + rifabutin-based
TB treatment
Reduce rifabutin dose to 150 mg daily or thrice
weekly. Monitor closely for rifabutin toxicity.
Ritonavir-boosted PIs markedly increase rifabutin
concentrations and reduce its clearance necessitating
reduction in the dose of rifabutin by 50% to 75%. Toxicity
(neutropenia, uveitis, hepatoxicity, rash, gastrointestinal
symptoms) and suboptimal rifamycin exposures with
reduced dose are concerns.
Triple nucleoside/tide regimen +
rifampicin-based TB treatment
No dose adjustments. A triple nucleoside/tide
regimen should include tenofovir or abacavir.
Monitor viral load.
Triple nucleoside/tide regimens may perform adequately in
patients with viral suppression who have not failed a first
line regimen, and provide alternative ART regimens in
patients with contraindications to efavirenz or nevirapine,
wehre other options are unavailable. TB treatment has
minimal effect on tenofovir concentrations. Although
rifampicin induces the enzymes responsible for
glucuronidation of abacavir and zidovudine, this effect is
not thought to be clinically important.
3TC 2′,3′-dideoxy-3′-thiacytidine, ART antiretroviral therapy, CYP cytochrome P450, EFV efavirenz, FTC emtricitabine, OATP organic anion-transporting polypeptide,
NNRTI non-nucleoside reverse transcriptase inhibitor, NVP nevirapine, PI protease inhibitor, TB tuberculosis, TDF tenofovir, WHO World Health Organization.
Table 4 Impact of co-trimoxazole prophylaxis on mortality among predominately adult patients with HIV-associated
tuberculosis (TB)
Study Year of publication Study design Country Level of bacterial
resistance to
co-trimoxazole
No. of study
participants
Mortality
reduction
Wiktor et al. [40] 1999 Randomized controlled trial Cote D’Ivoire Low 771 46%
Zachariah et al. [41] 2003 Cohort study (‘before’ and ‘after’
study with historical controls)
Malawi (north) High 1,986 19%
Mwaungulu et al. [42] 2004 Cohort study (‘before’ and ‘after’
study with historical controls)
Malawi (south) High 717 22%
Grimwade et al. [43] 2005 Cohort study (‘before’ and ‘after’
study with historical controls)
South Africa High 3,325 29%
Nunn et al. [44] 2008 Randomized controlled trial Zambia High 1,003 21%
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Triple nucleoside/tide regimens are less effective than
NNRTI-based or PI-based regimens particularly in pa-
tients with baseline viral loads >100,000 copies/ml [64].
However, small uncontrolled studies suggest they may
provide an acceptable regimen for TB patients who have
not failed an ART regimen [65,66] even though the con-
centrations of abacavir and zidovudine may be reduced
by concomitant RIF. This therefore provides an alterna-
tive option for those in whom EFV and NVP are contra-
indicated and integrase inhibitors unavailable.
Pharmacokinetic interactions with second-line ART
With increasing numbers of patients switching to prote-
ase inhibitor (PI)-based second-line ART regimens, de-
fining safe and effective approaches to concurrent TB
treatment is an urgent challenge. The pharmacokinetic
interactions between rifamycins and PIs are extensive.
RIF reduces concentrations of ritonavir-boosted PIs by
75% to 90% [67]. Conversely, through potent inhibition
of CYP3A4 and p-glycoprotein, high-dose ritonavir off-
sets the effect of RIF-mediated induction such that
‘superboosting’ of lopinavir or saquinavir (lopinavir/rito-
navir 400 mg/400 mg or saquinavir/ritonavir 400 mg/
400 mg, twice daily) preserves plasma concentrations of
the PI [68-70]. Adequate plasma concentrations of lopi-
navir are also achieved in adults by doubling the dose of
lopinavir/ritonavir in the tablet formulation (to 800/200
mg twice daily); this is the simplest approach, especially
in settings where the separate ritonavir is not available
[71]. Although these approaches are associated with
high rates of hepatotoxicity in studies of healthy volun-
teers, these seem to be much safer in HIV infected pa-
tients [71-76]. Nevertheless, hepatotoxicity, gastrointestinal
side effects and poor tolerability are problematic and
treatment discontinuation rates of up to nearly 50% have
been reported [74,75].
Rifabutin is an alternative rifamycin to RIF, but data
on its use in TB patients receiving ritonavir-boosted PIs
are limited. Studies of healthy volunteers show that
ritonavir-boosted PIs increase the concentrations of rifa-
butin approximately fourfold and the concentrations of
the active metabolite to an even greater extent. Thus,
the dose of rifabutin needs to be reduced. Thrice weekly
150 mg doses of rifabutin in combination with standard
doses of lopinavir/ritonavir may be reasonably tolerated
[77,78]. However, contrary to expectations based on
pharmacokinetic data from healthy volunteers, small
studies in coinfected patients have found that rifabutin
150 mg used thrice weekly in combination with lopina-
vir/ritonavir resulted in low rifabutin concentrations
[79-82]. Such levels would be conducive to acquisition
of rifamycin resistance in patients with severe immuno-
suppression [79,83] as has been observed with twice
weekly doses [84]. Thus, recent US national guidelines
recommend a daily 150 mg dose of rifabutin for patients
on ritonavir-boosted PIs [85].
There is extremely limited information about the
safety or efficacy using rifabutin with PIs and this may
vary between populations due to differential increases in
rifabutin concentrations. Severe neutropenia and uveitis
occur relatively frequently in patients with increased ex-
posures [81,86] and hepatitis, gastrointestinal symptoms,
rashes and anemia are also important safety concerns
[87,88]. While rifabutin is becoming more widely avail-
able and affordable, it is not an ideal solution for high
burden settings where limited patient monitoring is
available and fixed dose drug formulations are preferred.
Thus, there is an urgent need for research to define the
optimum approaches for the cotreatment of patients
with TB who have failed first-line ART, including the use
of newer agents.
Pharmacokinetic interactions with newer ART drugs
Ritonavir-boosted darunavir has a favorable safety and
tolerability compared to lopinavir/ritonavir and promis-
ing efficacy, especially in treatment of ART-experienced
patients. A pharmacokinetic study in healthy volunteers
suggests that it could be used in standard doses with
rifabutin 150 mg thrice weekly, but the drug-drug inter-
actions with RIF have not been studied. Integrase inhibi-
tors have potent antiviral activity and are well tolerated,
but any future role in ART programs in low-resource
settings is at present undefined. However, initial data on
use with TB treatment show promise. Pharmacokinetic
studies suggest that doubling the dose of raltegravir to
800 mg twice daily compensates for the effect of RIF on
overall exposure [89,90] and this approach seems to be
well tolerated and effective in patients with HIV-
associated TB [91]. However, preliminary results of the
REFLATE TB study suggest that such dose adjustment
may not even be necessary as virological responses were
similar in ART-naive TB patients receiving RIF who
were randomized to receive 400 mg or 800 mg of ralte-
gravir twice daily or EFV daily [92]. Similar to raltegravir,
a pharmacokinetic study of dolutegravir in healthy vol-
unteers suggests that the effect of RIF on antiretroviral
therapy can be overcome by increasing the daily 50 mg
dose of dolutegravir to 50 mg twice daily and that dose
adjustment may not be necessary with rifabutin [93].
Timing of ART initiation during TB treatment
The optimum time to start ART in patients with HIV-
associated TB is subject to a complex series of competing
risks [94] and must balance the high risk of morbidity
and mortality in patients with very low CD4 cell counts
and severe disease with the potential occurrence of
additive toxicities and immune reconstitution inflam-
matory syndrome (IRIS). Results of large randomized
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strategy trials are now available to inform guidelines
(Table 6) [48,55,95-98]. Patients with baseline CD4
counts of <200 and 200 to 500 cells/μl have improved
survival benefit from coadministered ART [48] and
WHO recommends that ART be given to all patients
concurrently with TB treatment regardless of the CD4
count. Trial data also demonstrated that mortality was
reduced in those with the most severe immunodeficiency
(CD4 cell counts <50 cells/μl) if they stated ART within
the first 2 weeks of TB treatment [11]. For patients with
less severe immunosuppression (CD4 counts >50 cells/μl),
data suggested that ART might be deferred until com-
pletion of the intensive phase of TB treatment without
compromising survival but reducing the risk of morbid-
ity from TB-IRIS [55,96].
WHO guidelines reflect these findings, recommending
that TB treatment should be started first and followed
by ART as soon as possible within the first 8 weeks of
treatment but within the first 2 weeks for those with
profound immunosuppression (CD4 count <50 cells/μl)
[11]. However, CD4 count measurements may either
be unavailable or be inaccurate in some settings. In
addition, within different CD4 count categories, there is
great diversity in severity of disease and mortality risk.
Thus, where feasible, decisions on timing for individual
patients might also be further informed by taking into
account clinical criteria such as body mass index, Karnofsky
score, severity of anemia and extent of TB. Moreover,
national guidelines might best be appropriately tailored
for operational simplicity. One possible option, for ex-
ample, might be to start ART in all patients after 2
weeks of TB treatment, accepting lower risk of mortal-
ity but higher risk of TB IRIS.
Patients with HIV-associated TB meningitis represent
an important exception. A randomized trial from Viet
Nam found no survival benefit from early ART in pa-
tients with TB meningitis [97], reflecting the awful prog-
nosis (mortality approximately 60%) of these patients
with advanced disease and the dire consequences of TB-
IRIS within the confined space of the CNS [99]. Further
studies are required in different geographical settings to
better define appropriate management of these patients.
Adverse drug reactions and management
Antituberculosis and antiretroviral drugs have overlapping
toxicity profiles that include drug-induced liver injury
(DILI), cutaneous reactions, renal impairment, neuropathy
and neuropsychiatric adverse effects (Table 7). These com-
plicate management in a substantial minority of patients.
In patients without coinfection, DILI (variably defined
as, for example, an elevation of alanine aminotransferase
to >3 or >5 times the upper limit of the normal range)
occurs in 5% to 33% of those receiving TB treatment
[100] and in 5% to 11% of those receiving currently
recommended ART regimens [101,102]. HIV infection
itself has been identified as a risk factor for DILI in pa-
tients receiving TB treatment in some [103,104] but not
all studies [105-108]. Of the currently used ART drugs,
NVP is associated with highest risk of DILI; however,
EFV and PIs are also recognized causes.
Concurrent TB treatment in patients receiving NNRTI-
based ART has been associated with an increased risk of
DILI in some [109-111] but not all [54] studies. In one of
these, the absolute risk of severe hepatotoxicity in patients
receiving EFV-based ART was low, but the risk associated
with concurrent TB treatment exceeded that associated
with positive hepatitis B surface antigen status [109]. Im-
portantly, a randomized trial of NVP-based versus EFV-
based ART in patients receiving TB treatment reported
more treatment discontinuations related to DILI in the
NVP arm (4 vs 0%) [56].
Development of DILI significantly complicates man-
agement of HIV-associated TB. Elevation of alanine
transaminase (ALT) concentrations >3 to 5 times the
upper limit of normal especially when accompanied by
symptoms or jaundice requires that all potentially hep-
atotoxic medication is interrupted until derangements of
liver function tests resolve. Thereafter, rechallenge of
first-line TB medication should be considered followed
by ART, although rechallenge is generally not under-
taken if there was liver failure. Rechallenge strategies
have not been studied in randomized trials in HIV-
infected patients. However, in the largest randomized
trial of TB without HIV coinfection, approximately 90%
of patients were rechallenged with their first-line TB
drugs without recurrence [112]. Risk of recurrence was
not related to whether the four first-line TB drugs were
reintroduced sequentially or concurrently. Further stud-
ies are needed to define the optimum rechallenge strat-
egy in coinfected patients in whom both TB treatment
and ART require reintroduction. Until further evidence
emerges, the American Thoracic Society recommends
that RIF can be reintroduced in coinfected patients once
the ALT is less than two times the upper limit of normal
followed by reintroduction of INH with monitoring of
liver function [100]. However, they also suggest that pyr-
azinamide is not reintroduced.
While some cohort studies have suggested low mor-
bidity and mortality in HIV-infected patients with DILI
[109], mortality is substantial among those requiring
hospital admission. In a South African study, mortality
was 35% among patients admitted to hospital with DILI
during TB treatment, ART or concurrent therapy [113].
Reasons for these deaths were sepsis and liver failure, al-
though interruption of required TB treatment and ART
are likely to have played a role.
TB treatment is associated with a spectrum of cutane-
ous adverse reactions including morbiliform rashes,
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Table 6 Randomized controlled studies of the timing of starting antiretroviral therapy (ART) during tuberculosis (TB) treatment
Study Study population Methods Results
N Location TB Median CD4+
cells/mm3 (IQR)
Timing of ART
in weeks ‘earlier’
vs ‘later’
Primary
endpoint
Follow-up
in months
Primary endpoint
‘earlier’ vs ‘later’a
Primary endpoint
in CD4 <50 cells/μlb
TB immune
reconstitution
SAPIT [48] (first analysis) 429 South Africa Smear-positive
pulmonary TB
150 (77 to 254) <12 vs after end
TB treatment
Death 12.1 5.4 vs 12.1
P = 0.003c
Not reported 12.4% vs 3.8%
P <0.001
SAPIT [96] (second
analysis)
429 South Africa Smear-positive
pulmonary TB
150 (77 to 254) Within 4 vs 8
to 12
AIDS or death 17.7 6.9 vs 7.8
P = 0.73
8.5 vs 26.3b
P = 0.06
20.1% vs 7.7%
P <0.001
CAMELIA [95] 660 Cambodia Smear-positive TB 25 (11 to 56) 2 vs 8 Death 25 18% vs 27%,
P = 0.006
Not reportedd 33.1% vs 13.7%
P <0.001
STRIDE [55] 809 Multicontinente Confirmed or
presumed
pulmonary or
extrapulmonary TB
77 (36 to 145) 2 vs 8 to 12 AIDS or death 12 12.9% vs 16.1%
P = 0.45
15.5% vs 26.6%
P = 0.02
11% vs 5%
P = 0.02
TB Meningitis [97] 253 Vietnam TB meningitis 39 (18 to 116) ≤1 vs 8 Deathf 12 59.8% vs 55.6%
P = 0.50
63.3% vs 65.1%
P = 0.84
Not reported
TIME Trial [98] 156 Thailand Confirmed or
presumed
pulmonary or
extrapulmonary TB
43 (37 to 106) 4 vs 12 Death 96 weeks 7.6% vs 6.5%
P >0.99
8.7% vs 13.1%
P = 0.725
8.86 vs 5.02
P = 0.069
Footnotes:
aPresented either as cumulative incidence of primary endpoint in early vs. later arm (%) or as events per 100 person-years.
bPrespecified analysis.
cSignificant difference in mortality observed in patients with either CD4 counts <200 cells/μl or 200 to 500 cells/μl.
dLower CD4 was not associated with an increased risk for the primary endpoint.
eNorth America, South America, Asia, Africa.
fPrimary endpoint was all cause mortality at 9 months.
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Steven Johnson syndrome and toxic epidermal necrolysis,
fixed drug eruption, lichenoid drug eruptions and acute
generalized exanthematous pustulosis [114]. Cotrimoxa-
zole, NVP, and to a lesser extent EFV, can also cause many
of the same clinical presentations [102,115,116]. HIV coin-
fection was associated with a fivefold increased risk of rash
or drug fever in one study [117] but small, non-significant
increases in risk in others [105,108]. If a clinically signifi-
cant rash develops, all potentially responsible drugs need
to be interrupted and then a carefully monitored rechal-
lenge of first-line TB drugs can be considered once the
rash has resolved. In a cohort of mainly HIV-infected pa-
tients rechallenged following cutaneous reactions to TB
drugs, 50% developed reintroduction reactions but only a
small minority were severe [118].
Renal dysfunction may be caused via different mecha-
nisms in patients receiving tenofovir, RIF or aminoglyco-
sides (used for MDR-TB). Tenofovir and aminoglycosides
may both cause tubular cell toxicity at the level of the
proximal renal tubules, whereas RIF infrequently causes a
tubulointerstitial nephritis mediated by immune hypersen-
sitivity. Case reports describe renal failure in patients re-
ceiving a combination of tenofovir and aminoglycosides,
although cohort studies have not confirmed an increased
risk [119]. The combination is best avoided when possible.
In patients with significant renal dysfunction, Use of teno-
fovir should be avoided where possible and dosing of eth-
ambutol, NRTI drugs, some quinolones (ofloxacin and
levofloxacin) and certain other second-line antituberculo-
sis drugs (including cycloserine, para-aminosalicylic acid,
clofazamine and linezolid) needs to be adjusted.
TB Immune reconstitution inflammatory syndrome (IRIS)
Two major forms of TB immune reconstitution syn-
drome (TB-IRIS) are recognized and these are called
paradoxical TB IRIS and unmasking TB-IRIS and case
definitions have been published [120]. Paradoxical TB-
IRIS is an important cause of morbidity in patients
known to have HIV-associated TB and occurs within the
first weeks of ART [120,121]. The typical clinical course
of paradoxical TB-IRIS is as follows. Initiation of TB
treatment in a patient with HIV infection and newly di-
agnosed TB results in clinical stabilization or improve-
ment. However, subsequent introduction of ART is
accompanied by recurrence or exacerbation of TB symp-
toms with new or worsening clinical signs of TB that
often have a marked inflammatory component [120,121].
While seldom life-threatening, deaths due to paradox-
ical TB-IRIS have been described. Two major risk factors
identified in observational studies [122-125] and in clin-
ical trials [55,95,126] are a low CD4 count prior to ART
and a shorter interval between starting TB treatment
and ART. There is no diagnostic test for TB-IRIS; the
diagnosis is based on clinical presentation and exclusion
of alternative diagnoses such as bacterial infection or
drug resistant TB [120]. However, drug-resistant TB is
not only in the differential diagnosis as an alternative
cause of the clinical deterioration but may also be a risk
factor for the development of paradoxical TB-IRIS [127].
The second major form of TB-IRIS is commonly re-
ferred to as ‘unmasking’ TB-IRIS. This occurs when ac-
tive TB is present but remains undiagnosed at the time
of starting ART [120,128]. Subsequent immune recovery
triggers the overt symptomatic presentation of TB. In a
proportion of cases, unusual inflammatory features may
also develop and such cases are regarded as having
‘unmasking’ TB-IRIS. Risk of unmasking TB-IRIS is
therefore directly related to the efficiency of the pre-
ART screening process and the resulting prevalence of
undiagnosed disease.
Table 7 Shared side effects of antiretroviral therapy (ART) and antituberculosis drugs
Adverse effects Antiretroviral drugs Antituberculosis drugs
Gastrointestinal disturbance and/or pain AZT, ddI, PIs RIF, INH, PZA, ethionamide, PAS, clofazamine, linezolid
Liver injury NVP, EFV, PIs, NRTIsa RIF, INH, PZA and many second line drugs including
ethionamide, fluoroquinolones, PAS
Peripheral neuropathy D4T, ddI INH, ethionamide, terizidone/cycloserine, linezolid
Neuropsychiatric EFV Terizidone/cycloserine, ethionamide, fluoroquinolones, INH
Renal impairment TDF Aminoglycosides and capreomycin
Rash NVP, EFV, ABC Rifampicin, INH, PZA, ethambutol, streptomycin and many
second line drugs including fluoroquinolones, PAS, clofazamine
Blood dyscrasias AZT, 3TC Linezolid, rifabutin, INH, rifampicin
Cardiac conduction abnormalities PIs Bedaquiline, fluoroquinolones, clofazamine
Pancreatitis D4T, ddI Linezolid
Lactic acidosis D4T, ddI Linezolid
3TC 2',3'-dideoxy-3'-thiacytidine, ABC abacavir, AZT zidovudine, D4T stavudine, ddI didanosine, EFV efavirenz, INH isoniazid, NRTIs nucleoside reverse transcriptase
inhibitors, NVP nevirapine, PAS para-aminosalicylic acid, PIs protease inhibitors, PZA pyrazinamide, RIF rifampicin, TDF tenofovir.
aNRTIs (especially D4T and ddI) can cause steatohepatitis.
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Both types of TB IRIS have a wide range of clinical fea-
tures often with involvement of multiple organ systems,
reflecting widespread dissemination of M. tuberculosis in
those with profound immunosuppression. Common fea-
tures include fever, recurrence of respiratory symptoms
with worsening infiltrates on chest radiographs, enlarge-
ment of lymph nodes (often with suppuration), formation
of tuberculous abscesses and serous effusions [120,121].
There are many case reports of unusual and diverse com-
plications, including granulomatous nephritis with renal
impairment, parotitis, epididymo-orchitis, granulomatous
hepatitis, splenic enlargement and abscess formation, psoas
abscess, peritonitis, ascites and intestinal involvement
[120,121]. Neurological TB-IRIS is particularly severe, man-
ifesting with tuberculomas, tuberculous abscesses, cerebral
edema, meningitis and radiculomyelopathy [99,129,130].
Neurological TB IRIS has a much poorer outcome com-
pared to other forms, with a mortality of 13% to 75%
[99,129,130].
In most cases, the onset of paradoxical TB-IRIS is
within the first 4 weeks of ART (median 14 days (IQR, 8
to 23) in 1 series [127]) but can occur within a few days.
The proportion of patients affected ranges widely from
0% to over 40% [120] and this may relate to differences
in risk factors and case definitions. In a meta-analysis,
the summary risk estimate was 15.7% [131]. Of these,
3.2% died, representing approximately 1 in 200 patients
with HIV-associated TB who start ART. The median
duration of TB-IRIS symptoms has been reported to be
2 to 3 months [124,125] but a minority of cases have a
protracted course which may last for more than 1 year
[120,124,132]. Such protracted cases typically have per-
sistent or recurrent suppurative lymphadenitis or abscess
formation. However, the majority of cases have a favor-
able long-term outcome [133].
TB-IRIS is not an indication for stopping ART, although
this should be considered in life-threatening cases such as
those with cerebral edema and depressed level of con-
sciousness or severe respiratory failure. In mild cases, no
specific treatment is usually required; the patient should
be treated symptomatically and counseled regarding the
need to continue ART and TB treatment. Corticosteroids
should be considered if symptoms are more significant.
In a randomized placebo-controlled trial, prednisone
used at a dose of 1.5 mg/kg/day for 2 weeks followed
by 0.75 mg/kg/day for 2 weeks was associated with re-
duced morbidity (duration of hospitalization and need for
therapeutic procedures) [134]. Symptom improvement
was more rapid and there was no excess risk of other se-
vere infections [134]. Although no mortality benefit was
demonstrated, patients with immediately life-threatening
TB-IRIS were not enrolled in view of ethical consider-
ations. Indeed, most experts recommend steroid therapy
for life-threatening TB-IRIS, especially IRIS involving the
CNS. A subgroup of patients in this trial (approximately
one in five) relapsed after stopping prednisone and re-
quired a further and more prolonged course to control
symptoms [134]. Similarly, in other settings, TB-IRIS has
relapsed in up to 50% of patients after stopping steroids
[133] and thus the duration of therapy must be tailored ac-
cording to the clinical response.
Non-steroidal anti-inflammatory drugs (NSAIDs) have
also been used in the treatment of TB IRIS although no
clinical trial data exist to support their use. Other forms
of immunomodulatory therapy such as thalidomide, aza-
thioprine and tumor necrosis factor α blockers (such as
adalumimab) have been used in cases refractory to ster-
oid therapy with anecdotal reports of benefit [135]. In
patients with suppurative lymphadenitis or abscesses,
needle aspiration may provide a pus sample to exclude
drug-resistant TB as well as bringing symptomatic relief.
There is no evidence base for pharmacological pre-
vention of TB-IRIS. However, this needs to be consid-
ered in view of the recommendation within guidelines
for early ART initiation in TB patients with advanced
HIV [11]. Adjunctive immunomodulatory therapies might
reduce the risk or severity of TB-IRIS in such patients.
A randomized placebo-controlled trial of prednisone
for prevention of TB-IRIS in high-risk patients (CD4
counts <100 cells/mm3 starting ART within 30 days of
TB treatment) is underway [136]. Until results from
this trial are available corticosteroids cannot be recom-
mended for prevention of TB IRIS with the exception
of patients with TB of the CNS for whom adjunctive
steroids form part of the standard of care [137]. How-
ever, in such patients, TB IRIS occurs in approximately
50% of patients with CNS TB starting ART despite re-
ceipt of corticosteroids [99].
Other agents that have been proposed for prevention
of TB IRIS are vitamin D, statins and the C-C chemo-
kine receptor type 5 (CCR5) blocker maraviroc [135].
Vitamin D has modulating effects on both the adaptive
and innate immune responses [138,139]. Statins have
anti-inflammatory properties and there is precedence for
using these agents for autoimmune inflammatory disor-
ders in an experimental model [140,141]. However, nei-
ther vitamin D nor statins have yet been tested in
clinical studies. Maraviroc, however, was shown not to
prevent IRIS in a placebo-controlled trial conducted in
Mexico and South Africa [142].
Management of HIV-associated MDR-TB
The emergence of MDR-TB and extensively drug resistant
TB (XDR-TB) has compounded the HIV-associated TB
epidemic in resource-limited settings [5,143]. MDR-TB is
caused by strains that are resistant to both rifampicin and
isoniazid whereas XDR-TB strains are MDR-TB strains
with additional resistance to any quinolone drug and any
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one of the second-line injectable aminoglycosides (amika-
cin, capreomycin or kanamycin). Much disease remains
undiagnosed due to lack of laboratory capacity. However,
increasing implementation of the Xpert MTB/RIF assay
now provides the means for rapid screening for RIF re-
sistance, although follow-on testing is then required to
further characterize the full drug susceptibility pattern.
This can be performed phenotypically through culture-
based systems but is very slow. In 2008, WHO approved
the use of line probe assays for the rapid molecular detec-
tion of drug resistance in smear-positive specimens or cul-
ture isolates [144] and a range of commercially available
assays now offer the possibility of much more rapid diag-
nosis of both MDR-TB and XDR-TB [145]. However,
line-probe assays can only be used where appropriate la-
boratory facilities and expertise exist as they are highly
technically demanding and are well beyond the scope of
most resource-limited settings apart from in specialized
reference laboratories.
Worldwide, successful treatment of MDR-TB is achieved
in only approximately 50% to 60% of patients [146,147],
but management is considerably more difficult in resource-
limited settings and especially in those with HIV coin-
fection due to late diagnosis with more frequent extra-
pulmonary dissemination, high risks of drug cotoxicity
and IRIS, copathology and poor adherence with pro-
longed, toxic regimens. The WHO recommends that
patients with confirmed MDR-TB should receive a
regimen containing pyrazinamide together with at
least four second-line drugs in the intensive phase that
are likely to be effective, including a fluoroquinolone
(using a later generation agent where possible), a par-
enteral agent (such as amikacin or kanamycin), ethi-
onamide (or prothionamide) and either cycloserine or
p-aminosalicylic acid (PAS) [13]. An intensive phase of 8
months and a total treatment duration of 20 months is sug-
gested for most patients, but may be modified according to
response. A range of other second-line drugs that have lim-
ited efficacy may be used for treatment of XDR-TB and
treatment regimens should be based upon drug susceptibil-
ity testing [13]. However, evidence to inform best practice
is lacking and outcomes are often poor.
Co-trimoxazole prophylaxis and ART are recom-
mended for all patients with HIV-associated MDR-TB
regardless of CD4 count and the timing of ART initi-
ation is similar as for drug-susceptible TB [11]. Many of
the second-line MDR-TB drugs are poorly tolerated and
drug discontinuation rates are high as a result of adverse
effects. MDR-TB may be a risk factor for TB IRIS in
view of slow mycobacterial antigen clearance [127]. Nu-
tritional depletion and co-morbid conditions may further
undermine outcomes.
Adverse events are frequent in HIV-infected patients receiv-
ing MDR treatment, the most common being gastrointestinal
symptoms, peripheral neuropathy, hypothyroidism, deafness,
psychiatric symptoms and hypokalemia [148,149]. In up
to 40% of patients these adverse events are severe
[148]. This relates to the inherent toxicity associated
with MDR drugs; it does not appear that HIV-infected
patients experience a higher incidence of adverse events
than HIV-uninfected patients, nor that coadministration
with ART increases toxicity [148,150,151].
Antiretroviral drugs do share common toxicities with
second-line antituberculosis drugs, however (Table 7).
Some of the most challenging of these are neuropsychi-
atric side effects. EFV causes inattention, vivid dreams
and dizziness in up to 50% of patients, but in a minority
these can be severe with mood disturbance or psychosis.
Cycloserine (or terizidone) is a well recognized cause of
psychosis, seizures and other CNS side effects although
several other drugs such as the quinolones, ethionamide
and high dose isoniazid can also cause CNS side effects.
If patients develop severe CNS side effects it may be ne-
cessary to withdraw all possible culprit drugs with care-
ful sequential reintroduction once resolved. Cycloserine
should probably be regarded as the most likely culprit
for psychosis and seizures. Antipsychotic or antidepres-
sant medications may be required. EFV should not be
routinely avoided because the majority of MDR-TB pa-
tients tolerate it well.
Much research is needed on how to improve treatment
for drug-resistant TB. A shortened MDR-TB regimen of 9
months, which was found to be effective and well tolerated
in Bangladesh [152], is now being evaluated in Ethiopia,
South Africa and Vietnam and includes patients with
HIV-associated TB. In the future, the newly approved
agent bedaquiline (TMC-207) as well as two new nitroimi-
dazoles (PA-824 and delaminid (OPC67683) under evalu-
ation) may offer the prospects of improved treatment for
MDR-TB [38]. However, a prolonged timeline is needed
to adequately define how to combine existing agents
and new drugs in regimens that optimize outcomes and
that can be combined with ART in those with HIV-
associated TB.
Conclusions
The HIV-associated TB epidemic is a major challenge
to international public health, remaining the most im-
portant opportunistic infection in people living with
HIV globally and accounting for nearly 0.5 million
deaths each year. However, over the past 10 years,
major progress has been achieved in defining guidelines
for the optimum case management with a combination
of co-trimoxazole prophylaxis, optimally timed ART,
and diagnosis and appropriate supportive care for treat-
ment complications including drug toxicity and IRIS.
The major remaining challenges are the management
of TB in the increasing proportion of patients receiving
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PI-containing ART and the management of drug resistant
TB. Having defined case management strategies, the
ongoing challenge is to further develop effective, com-
prehensive and sustainable means of delivery through
health systems.
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